Abstract Despite acceptance that R-CHOP is optimal known therapy for diffuse large B-cell lymphoma, delivering R-CHOP in elderly patients remains a common and significant challenge. Twentieth century studies suggested that the oldest of older patients received lower dose intensities of CHOP and experienced inferior survival. New data presented in this issue compares detailed dosing information with R-CHOP in patients over age 70 to younger patients and looks at disease-specific clinical outcomes. This information coupled with future studies may help us get to personalized dosing strategies for older patients.